LMN-201 for Preventing C. Difficile Infection Recurrence
This study is testing a new treatment called LMN-201 for people who have recently been diagnosed with *Clostridioides difficile* infection (CDI). CDI is a serious gut infection that causes severe diarrhea. LMN-201 is made from a type of spirulina (a blue-green algae) that has been modified to help fight the C. difficile toxins. You would receive either LMN-201 or a placebo (an inactive substance that looks the same) while also getting standard antibiotic treatment for C. difficile. The main goal is to see how many participants achieve a global cure, meaning their infection is gone, up to 16 weeks after starting treatment. This is a multisite study and aims to enroll 375 participants. You can join if you are 18 years or older, have a recent diagnosis of CDI confirmed by a stool test, and have ongoing diarrhea.
- Study design
- This is an interventional study, meaning participants receive a specific treatment. It is a multisite study and plans to enroll 375 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 16 weeks after starting treatment to assess for global cure.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
LMN-201 for Prevention of C. Difficile Infection Recurrence
At a glance
Conditions
Where it's being run
15 sites across 12 statesWho to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Proportion of participants who achieve global cureUp to 16 weeks after initiation of therapy
Proportion of total participants with both successful initial CDI treatment and no CDI recurrence during the Prevention and Observation Phases (by treatment assignment).